Literature DB >> 29945109

A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of valacyclovir and its metabolite acyclovir in mouse and human plasma.

Jian Shi1, Yongjun Hu2, David E Smith2, Hao-Jie Zhu3.   

Abstract

It is challenging to conduct a pharmacokinetic (PK) study on mice due to the limited amount of plasma one can obtain, which is also true for some clinical studies. Here, we developed and validated a simple, sensitive and robust LC-MS/MS method for measuring the prodrug valacyclovir (VACV) and its metabolite acyclovir (ACV) in mouse and human plasma. This assay utilized an acetonitrile protein precipitation method with isotope-labeled internal standards (IS) and enabled precise and accurate quantification of VACV and ACV in 10 μL plasma samples with a nine-min gradient. The analytes were separated on a Waters Atlantis T3 C18 column. The precursor-product ion transitions for VACV (m/z 325.2 > 152.1), ACV (m/z 226.2 > 152.1), VACV-D4 (m/z 329.2 > 152.1, IS) and ACV-D4 (m/z 230.2 > 152.1, IS) were detected in a multiple reaction monitoring (MRM) positive ion mode using an API4000 LC-MS/MS system. The lower limit of quantification (LLOQ) was 2 nM for both VACV and ACV. The linear range was validated over the concentration ranges of 2-200 nM and 200-5000 nM for both compounds. The matrix effect and stability of VACV and ACV were also evaluated. This assay was successfully applied to a PK study in mice.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acyclovir; LC-MS/MS; Mouse; Plasma; Valacyclovir

Mesh:

Substances:

Year:  2018        PMID: 29945109      PMCID: PMC6882412          DOI: 10.1016/j.jchromb.2018.06.040

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?

Authors:  Ellen Stokvis; Hilde Rosing; Jos H Beijnen
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

2.  Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method.

Authors:  Manish Yadav; Vivek Upadhyay; Puran Singhal; Sailendra Goswami; Pranav S Shrivastav
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-02-14       Impact factor: 3.205

3.  One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics.

Authors:  Alison P Joyce; Mengmeng Wang; Rosemary Lawrence-Henderson; Cynthia Filliettaz; Sheldon S Leung; Xin Xu; Denise M O'Hara
Journal:  Pharm Res       Date:  2014-01-24       Impact factor: 4.200

Review 4.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

Review 5.  Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.

Authors:  K R Beutner
Journal:  Antiviral Res       Date:  1995-12       Impact factor: 5.970

6.  Analysis of the antiviral drugs acyclovir and valacyclovir-hydrochloride in tsetse flies (Glossina pallidipes) using LC-MSMS.

Authors:  J J Sasanya; A M M Abd-Alla; A G Parker; A Cannavan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-07-22       Impact factor: 3.205

7.  Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase.

Authors:  Insook Kim; Xiao-Yan Chu; Seonyoung Kim; Chester J Provoda; Kyung-Dall Lee; Gordon L Amidon
Journal:  J Biol Chem       Date:  2003-05-05       Impact factor: 5.157

8.  Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.

Authors:  P de Miranda; T C Burnette
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

9.  Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.

Authors:  T C Burnette; P de Miranda
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

Review 10.  New antiherpesvirus agents. Their targets and therapeutic potential.

Authors:  F A Alrabiah; S L Sacks
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

  10 in total
  3 in total

1.  Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice.

Authors:  Yongjun Hu; Daniel Epling; Jian Shi; Feifeng Song; Yasuhiro Tsume; Hao-Jie Zhu; Gordon L Amidon; David E Smith
Journal:  Biochem Pharmacol       Date:  2018-08-17       Impact factor: 5.858

2.  Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC-MS/MS.

Authors:  Andreas Ärlemalm; Anders Helldén; Louise Karlsson; Björn Carlsson
Journal:  Biomed Chromatogr       Date:  2022-01-28       Impact factor: 1.911

3.  Proposing a minimal set of metrics and methods to predict probabilities of amyloidosis disease and onset age in individuals.

Authors:  Richard S Criddle; Hsien-Jung L Lin; Isabella James; Ji Sun Park; Lee D Hansen; John C Price
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.